학술논문
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
Document Type
Article
Author
Source
In The Lancet Gastroenterology & Hepatology November 2022 7(11):1024-1035
Subject
Language
ISSN
2468-1253